The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. No vaccine-related serious adverse events (SAEs) were observed.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

JULY 21, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 25, 2021

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Moderna’s COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna’s pipeline. government.

Government 40

Government Vaccine RNA Science 40

The Pharma Data

FEBRUARY 22, 2021

State Premier of North Rhine-Westphalia Armin Laschet and Birgitta Radermacher, President of Duesseldorf Administrative District, today visited Bayer AG’s research and production site in Wuppertal to gain an insight into the planned vaccine production there. Effective vaccines are our best weapon to combat the pandemic.

Vaccine 40

Vaccine Production Virus Pharmaceuticals 40

BioPharma Drive: Drug Pricing

JULY 23, 2025

Called Dispatch Bio, the startup was formed in 2022 through a collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy and built around technologies from scientific labs in Pennsylvania and California. This flare is an antigen that a CAR-T therapy Dispatch subsequently administers is designed to seek out.

Therapies 303

Therapies Specialty Pharmacies Pharmacy FDA 303

The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

DECEMBER 18, 2020

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors. billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.

Vaccine 52

Vaccine Government International Virus 52

The Pharma Data

APRIL 18, 2022

Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. TAK-019 Clinical Trial.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

New Drug Approvals

DECEMBER 26, 2022

1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03 Immunoglobulin g1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal med18897.gamma.1-chain), 2] [3] Nirsevimab is designed to bind to the fusion protein on the surface of the RSV virus. [4]

Virus 52

Virus Clinical Trials Trials Disease 52

Agency IQ

MARCH 7, 2024

Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season.

Vaccine 40

Vaccine FDA Virus Licensing 40

Drug Target Review

JANUARY 15, 2024

Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells. Journal for ImmunoTherapy of Cancer 10:e004281 (2022).

Engineering 110

Engineering DNA Virus Medical Schools 110

Codon

APRIL 23, 2023

Most people would take the two CRISPR gene-editing components (a Cas9 protein and guide RNA), package them up inside of a virus, and then inject the viruses into the skulls of mice. Promising new malaria vaccine for kids approved in Ghana. This is not the first vaccine approved to prevent malaria, but it is by far the most effective.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

Most people would take the two CRISPR gene-editing components (a Cas9 protein and guide RNA), package them up inside of a virus, and then inject the viruses into the skulls of mice. Promising new malaria vaccine for kids approved in Ghana. This is not the first vaccine approved to prevent malaria, but it is by far the most effective.

Vaccine 52

Vaccine DNA Virus Engineering 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. Topline results for VLA15-221 are expected in the first half of 2022. at Month 7). About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Codon

MARCH 20, 2023

How cell-free processes could speed up vaccine development. How to build a virus-proof cell. 🏭 Industry SpyBiotech receives more than $4 million to develop vaccine platform. Reports Fourth Quarter and Full Year 2022 Financial Results. It’s Official: No More Crispr Babies—for Now. Gameiro DN.

Virus 52

Virus RNA Engineering Small Molecule 52

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Virus Hospitals Trials 40

The Pharma Data

MAY 16, 2022

The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics. It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7

Vaccine 52

Vaccine Hospitals Virus Disease 52

The Pharma Data

FEBRUARY 25, 2022

“The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. ” The findings published today (Feb.

FDA Approval 52

FDA Approval Molecular Biology FDA Virus 52

The Pharma Data

MARCH 29, 2022

Once approved, this compound could be used in combination with already available drugs that inhibit the virus’ replication, to provide a stronger defense against COVID-19 variants of concern,” says Dr. Jean, founder of FINDER, the state-of-the-art level three biocontainment facility where the work on SARS-CoV-2 variants was conducted.

Virus 52

Virus Small Molecule Research Clinical Trials 52

Agency IQ

JANUARY 19, 2024

For example, in 2023, the EMA published its 2022 highlights report on February 16, followed by the detailed report on May 15. This most recent year saw 80 total opinions, compared to 92 in 2022 and 97 in 2021. The EMA has now seen a three-year decline in new active substances, with 54 in 2021, 44 in 2022 and 39 in 2023.

Biosimilars 40

Biosimilars FDA Production Treatment 40

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1 – 5. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants.

Virus 40

Virus Trials Disease Hospitals 40

Agency IQ

JANUARY 19, 2024

The final version includes some extensive updates to a 2022 draft revision, to include reduced use of animals in testing and development of these products. Prevention of viral contamination is especially important as it may not be apparent that cells have been contaminated with a virus using conventional detection methods.

Virus 40

Virus Science Production FDA 40

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. population. The samples were stored after the researchers measured the T cell response.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

MARCH 11, 2021

At Crop Science we’re targeting above-market growth from 2022. Bayer is also displaying its sense of responsibility during the COVID-19 crisis, applying its knowledge and resources to help in tackling the virus – in line with the company’s vision “Health for all, Hunger for none.” Speeding up sales growth.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Premier Consulting Blog

JUNE 18, 2023

In 2022, the FDA published a report, Successes and Opportunities in Modeling & Simulation for FDA. The 2022 report, for example, describes how modeling and molecular dynamics simulations were used to elucidate interactions between SARS-CoV-2 trimeric spike protein and ACE2.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

Broad Institute

MARCH 22, 2024

McAlpine March 22, 2024 Credit: Catherine Boush, Broad Communications Related news New method tracks gene expression in single cells over space and time Messenger RNA (mRNA) made its big leap into the public limelight during the pandemic, thanks to its cornerstone role in several COVID-19 vaccines.

Engineering 140

Engineering Protein Production RNA Vaccine 140

Agency IQ

NOVEMBER 3, 2023

The Pharmaceutical Group of the European Union (PGEU) conducted a survey finding shortages worsened in 2022 compared to 2021, with most European countries reporting worsening. Regulation (EU) 2022/123 became applicable on March 1, 2022, with the exception of most provisions related to medical devices.

Regulations 40

Regulations International Pharmaceuticals Production 40

The Pharma Data

MARCH 25, 2022

Despite the roll-out of vaccines and antivirals, the need for effective therapeutics against severe COVID-19 infection remains high. Using electron cryo-microscopy, the researchers found that Fu2 naturally binds to two separate sites on the viral spike, thus inhibiting the virus’ ability to enter the host cell.

Molecular Biology 52

Molecular Biology Laboratories Cell Biology Science 52

EG Life Sciences

FEBRUARY 15, 2023

The year 2022 reflected a transformative path for the drug development industry. It is without a doubt that 2022 predicted change and opportunity in biopharma and biotech clinical trials in 2023. The US Food and Drug Administration (FDA) approved around 26 novel drugs in 2022.

Drug Development 52

Drug Development FDA Approval Drugs Virus 52

The Pharma Data

MARCH 8, 2022

The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. Camouflage protects virus from immune system.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

PerkinElmer

JANUARY 25, 2023

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. Experts in the diagnostics and life sciences industry look back on 2022 and lend their insights on the major trends and technologies shaping laboratories in 2023.

Science 52

Science Laboratories Immune Response Disease 52

Codon

APRIL 2, 2023

mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 Read How well do different antibodies, created by people who got two or three doses of the COVID-19 mRNA vaccine, fight off new viral variants, such as BA.4 from 2021 to 2022, up to $625 million. Andreano E. Nature Communications. Gene Therapy.

DNA 52

DNA RNA Engineering Licensing 52

Creative Biolabs

SEPTEMBER 6, 2022

Based on this discovery, scientists can develop new drugs to treat diseases and improve vaccines to prevent diseases by simulating the “super antibodies” produced by pregnant women. Nature 606, 769–775 (2022). Deacetylated anti-Lm antibodies protect via CD22-mediated suppression of B cell IL-10 production.

Vaccine 52

Vaccine Virus Clinical Trials Disease 52

Agency IQ

AUGUST 2, 2024

For example, the German medtech trade organization (BVMed) is hosting a webinar on September 9 to offer industry an overview of the upcoming launch of upcoming cybersecurity policy, European NIS-2 Directive ( EU 2022/2555 ) that aims to harmonize cybersecurity measures across the E.U

Regulations 40

Regulations Clinical Trials Production Trials 40

Codon

SEPTEMBER 29, 2024

The first model of life emerged sometime in 2022 or 2023. There was scFormer in 2022, scGPT in 2023, and plenty of others. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. Of particular interest was how genetic therapies were delivered.

Engineering 145

Engineering Virus DNA Therapies 145

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Top-line results are expected in the first half of 2022. ProQR – Netherlands-based ProQR Therapeutics N.V.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52